Tristan Mañalac

4 days ago | biospace.com | Tristan Mañalac

Sangamo Therapeutics’ investigational gene therapy isaralgagene civaparvovec improved kidney function in patients with Fabry disease, according to a Phase I/II readout from the company on Tuesday. Sangamo plans to use these results to build a case for an accelerated approval of the gene therapy. This news comes after an earlier data release, slim on details, from the biotech last month, announcing that it had met a “key milestone” for a regulatory filing for isaralgagene civaparvovec.

4 days ago | biospace.com | Tristan Mañalac

Sanofi has licensed gusacitinib, an oral JAK/SYK dual inhibitor from the “AI-native” drug development company Formation Bio, marking the pharma’s latest investment in AI-focused drug development. Terms of the deal, announced Monday, were sparse. The licensing agreement will involve upfront and milestone payments worth up to €545 million, or approximately $632 million, though the companies did not provide a specific breakdown of these numbers.

4 days ago | biospace.com | Tristan Mañalac

Eli Lilly’s antibody bimagrumab, when used alongside Novo Nordisk’s semaglutide, marketed as Wegovy, helps patients lose weight while also preserving their muscle mass. These results come from the placebo-controlled Phase IIb BELIEVE study, which enrolled more than 500 patients who were given subcutaneous semaglutide weekly and intravenous bimagrumab at weeks 4, 16, 28 and 40.

5 days ago | biospace.com | Tristan Mañalac

Exelixis’ third-generation tyrosine kinase inhibitor zanzalintinib, when used in combination with Roche’s PD-L1 blocker Tecentriq, outperforms Bayer’s Stivarga for the treatment of certain patients with colorectal cancer, according to a release from Exelixis. These findings, announced Sunday, mark “the first pivotal success from the zanzalintinib program,” William Blair analysts wrote in a Monday note.

5 days ago | biospace.com | Tristan Mañalac

After the underwhelming readout for CagriSema last December, Novo Nordisk came to the American Diabetes Association’s 85th scientific congress with new safety data for the drug, possibly hoping to rebuild investor confidence. Also over the weekend, Novo revealed mid-stage data for its GLP-1- and amylin-targeting drug amycretin, leading to dose-related questions.